Monoclonal gammopathy of renal significance : a nephrologist's perspective by Krzanowska, Katarzyna
Monoclonal gammopathy of renal significance: 
a nephrologists perspective
Katarzyna Krzanowska
Department of Nephrology, Jagiellonian University Medical College, Kraków, Poland
Introduction Hie current diagnostic criteria de­
fine monoclonal gam m opathy o f undeterm ined 
significance (MGUS), which is considered a benign 
p lasm a cell dyscrasia, include serum  M protein 
levels of less than 3 g/dl and bone marrow infiltra­
tion o f clonal p lasm a cells o f less than 10%, with 
no disease-related end-organ damage. Monoclonal 
gammopathy of renal significance (MGRS) fulfills 
the hematologic criteria for monoclonal gammop­
athy defined as a  heterogenic group o f disorders 
pathogenetically characterized by proliferation of 
a B-cell or plasm a cell clone. This sm all clone syn­
thesizes and secretes a monoclonal immunoglob­
ulin (Ig) or its components (light or heavy chains), 
which may be directly deposited in the kidneys 
or indirectly cause alternative complement path­
way dysregulation and cause glomerular, tubular, 
interstitial, or vascular dam age. The term  MGRS 
does not encom pass kidney disorders associated 
with large clone lym phoproliferative disorders, 
such as m ultiple m yelom a, W aldenstrom  mac- 
roglobulinemia, chronic lymphocytic leukemia, 
and malignant lymphoma. The prognosis for sur­
vival is more severe when compared with MGUS, 
because if untreated, MGRS leads to progression 
of kidney damage. Moreover, in MGUS treatm ent 
is not necessary, while in MGRS therapy is fun­
dam ental and has been shown to improve long­
-term outcom es.1-2
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Diagnosis of monoclonal gammopathy of renal sig­
nificance Hie diagnosis o f a  su spected  MGRS 
is based on the presence o f kidney dam age (pro­
gressive kidney failure, nephrotic syndrome and 
n onnephrotic proteinuria, Fanconi syndrom e, 
or tubulointerstitial dysfunction) in association 
with monoclonal peak in serum  electrophoresis. 
In m ost cases, the diagnosis is established using 
serum  and urine electrophoresis, and according 
to recom m endations, a  24-hour urine collection 
for electrophoresis is required. However, in cases 
where the concentration o f monoclonal protein 
in plasm a or urine is undetectable in convention­
al electrophoresis, p lasm a and urine immunofix- 
ation m ust be additionally perform ed. Immuno- 
fixation will identify the type o f monoclonal pro­
tein and determine whether free light chains are 
present in blood and urine. Interestingly, m ost
cases o f kidney dam age in MGRS are diagnosed 
mainly on the basis o f findings in kidney biop­
sy. Kidney biopsy is required for the diagnosis of 
MGRS, and m ust include im m unohistochem is- 
try, immunofluorescence, and electron microsco­
py. Monoclonal Ig deposition is involved in many 
types o f M GRS.2-4
Pathological studies may require electron mi­
croscopy because it allows a  proper character­
ization o f the ultrastructural organization o f Ig 
deposits. Importantly, the diagnosis o f amyloid 
light-chain (AL) am yloidosis requires n ot only 
Congo red staining of the biopsied tissue but also 
immunohistochemistry and immunoelectron mi­
croscopy or m ass spectrom etry. These m ethods 
are also used to exclude a late-onset hereditary 
form  of am yloidosis or the wild-type transthyre­
tin. Laser m icrodissection and m ass spectrom e­
try proteom ics are recom mended to confirm not 
only AL am yloidosis but also cases o f monoclo­
nal Ig deposition disease with truncated m ono­
clonal Ig or types where the specific monoclonal 
Ig region is o f interest. To identify a  pathologi­
cal clone, diagnostic workup should begin with 
a bone marrow biopsy, which in m ost cases is su f­
ficient for clonal identification. Flow cytom etry 
is im portant for identification o f sm aller clones, 
which may be often m issed by a histologic exam­
ination. It is im portant especially in the presence 
o f clonal p lasm a cells or B cells, even when mar­
row cellularity is below 5% of pathological marrow 
cells. When the bone m arrow specim en is nega­
tive for atypical p lasm a cells or B-cells, a  lymph 
node biopsy m aybe necessary. Positron emission 
tomography, com puted tomography, or m agnet­
ic resonance im aging may be helpful in locating 
adenopathy.15
Pathogenesis of renal damage in monoclonal gam­
mopathy of renal significance Two m ajor patho­
physiological m echanism s have been involved in 
MGRS: direct and indirect, which mainly depend 
on physicochem ical p rop erties o f m onoclonal 
Ig. Hie direct m echanism  is the m ost common. 
Here kidney dam age is induced by direct mono­
clonal Ig deposition. It is preceded by receptor­
-m ediated endocytosis into glom erular or tubu­
lar cells after monoclonal Ig has been filtered into
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FIGURE 1 Proposed algorithm for nephrologic workup in patients w ith  monoclonal gammopathy of renal significance
Abbreviations: AH amyloidosis, heavy-chain amyloidosis; AHL amyloidosis, heavy- and light-chain amyloidosis; AL amyloidosis, light-chain amyloidosis; 
GN, glomerulopathy; GOMMID, glomerulopathy w ith organized microtubular monoclonal deposits; HCDD, heavy-chain deposition disease; LC, light chain; 
LCDD, light-chain deposition disease; LHCDD, light- and heavy-chain deposition disease; MGRS, monoclonal gammopathy of renal significance; MIDD, 
monoclonal immunoglobulin deposition disease; PGNMIgD, proliferative glomerulopathy w ith monoclonal immunoglobulin deposits
Monoclonal gammopathy of renal significance: a nephrologist’s perspective 23
The algorithm for clinical approach of MGRS
Laboratory test:
Serum electrophoresis/immunofixation
Urine electrophoresis/immunofixation in 24 hour urine collection
Serum and urine free light chain
Bone marrow biopsy and 
aspirate/lymph node biopsy
Flow cytometry 
Immuriohistological studies 
Positron emission tomography/computed 
tomography/magnetic resonance imaging
Kidney biopsy
Light microscopy
Immunofluorescence
Electron microscopy
Immunoelectron microscopy
Laser rm icrodissection/m ass spectrometry
Criteria of MGRS diagnosis
<10%  clonal bone marrow plasma cell 
< 3  g/dl monocolonal protein 
Monoclonal lg-associated renal disease 
No myeloma-defining event
Clinical presentation of MGRS
Acute kidney injury Nephrotic syndrome Nephritic syndrome/RPGN Progressive CKD/nonnephrotic 
proteinuria
Direct mechanism— IF positive for monoclonal Ig
Cast nephropathy Amyloidosis (AL, AH, AHL) 
Fibrillary GN (FGN) 
Monoclonal Ig deposition 
disease (LCDD, HCDD 
LHCDD)
Proliferative GN w ith 
monoclonal Ig deposits 
(PGNMIgD)
Cryoglobuliriemic GN 
Amyloidosis
Immunotactoid GN/GOMMID
Monoclonal immunoglobulin 
deposition disease (LCDD, 
LHCDD, HCDD)
LC proximal tubulopathy (with 
or w ithou t Fanconi syndrome) 
Crystal storing histiocytosis
Thrombotic microangiopathy 
C4 dense-deposit disease
C3 glomerulopathy 
associated w ith monoclonal 
gammopathy
Indirect mechanism— IF negative for monoclonal Ig
Thrombotic
microangiopathy
Confirm monoclonal immunoglobulin and kidney damage associated w ith  monoclonal protein deposits 
Investigate alternative complement pathways 
Identify the pathological clone
Clone direct treatment (if identified) 
Autologous stem cell transplantation 
Kidney transplant
the urinary space. The indirect m echanism  de­
pends on monoclonal Ig acting as an autoanti­
body, as in the case o f C3 glom erulopathy and 
atypical hemolytic uremic syndrome. Here anti­
bodies influence dysregulation o f the liquid or 
solid phase o f the alternative complement path­
way; for example, an ti-factor H is the main an­
tibody involved in C3. A sim ilar m echanism  was 
also found in C4 dense deposit disease with dys­
regulation o f the mannose-binding lectin path­
way o f the com plem ent.2
The algorithm  for the clinical approach  to 
MGRS is presented in f ig u r e  1 .
Histologic findings Hie diagnosis o f MGRS re­
quires an analysis o f m orphologic alterations 
seen on light microscopy, electron microscopy, 
and im m unofluorescence, in correlation with 
clinical param eters. Immunofluorescence should 
be perform ed using panel antibodies specific for 
different light chains and monoclonal Ig isotypes.
A m on g the h isto log ic  lesio n s ob served  in 
MGRS, we distinguish organized and nonorga­
nized Ig deposits. Exam ples o f organized depos­
its are fibrillar Ig deposits, amyloidosis, fibrillary 
glomerulonephritis, microtubular Ig deposits, im- 
munotactoid glomerulopathy, type I cryoglobuli- 
nemic glomerulonephritis, and types with crystal 
inclusion (such as proximal tubulopathy, with or 
without Fanconi syndrome, and histiocytosis, in 
which the crystal deposits are not found in tu ­
bular epithelial cells but inside the histiocytes). 
On the other hand, histom orphological lesions 
include also  nonorganized Ig deposits such as 
proliferative glom erulonephritis with monoclo­
nal IgG deposits, C3 glomerulopathy with mono­
clonal gamm opathy, and m onoclonal im m uno­
globulin deposition disease.5 Clinical m anifesta­
tions o f the heterogeneous group o f diseases oc­
curring in MGRS are presented f ig u r e  1 .
Treatm ent of monoclonal gammopathy of renal sig­
nificance Every case o f MGRS should be con­
su lted  by a h e m ato lo g ist  fo r  erad ication  o f 
the clonal d isease . H ie m o st com m on m u lti­
drug treatm ent regim en that would be appro­
priate for the clones detected in MGRS disor­
ders includes cyclophospham ide, proteasom e 
inh ibitors (bortezom ib or carfilzom ib), dexa- 
m ethasone, bendam ustine, and rituxim ab. Im­
m unom odulatory agents (thalidom ide, lenalid- 
om ide, or pom alidom ide com bined with dexa- 
m ethasone) are also prescribed. In the future, 
anti-D38 monoclonal antibody (daratum um ab) 
can be u sed  fo r the treatm en t o f newly diag­
nosed MGRS, as in patien ts with m ultiple m y­
elom a. In MGRS caused by the indirect mecha­
nism (such as C3 glom erulonephritis and dense 
deposit disease), the use o f eculizumab may re­
su lt in the reduction o f proteinuria and serum  
creatinine levels. A fter hem atologic rem ission  
in patients with MGRS and end-stage renal dis­
ease, autologous stem  cell transplan tation  and 
kidney transplantation  should be considered.i4
MGRS is a  disease o f the kidney, secondary 
to a  B-cell or p lasm a cell clonal proliferation  
or the alternative pathway o f complement dys­
regulation and immune dysfunction. It requires 
a  therapeutic intervention to eradicate the of­
fending clone. U ntreated MGRS leads to kidney 
dam age and renal replacem ent therapy, w ors­
ening prognosis and decreasing survival in this 
patient group.
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